Search results for: IgG1
#33656935 
2021/03/03
To Up
Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients.
For the assessment of vaccine-induced immune response and to understand the role of antibodies in neutralization, it is necessary to assess dynamics of various antibodies in patients with different clinical manifestations. This study aims to quantitate circulating levels of IgA/IgG and IgG subtypes induced at different days postonset of symptoms, in severe and nonsevere patients. For this, serum or plasma samples ( = 146) collected from 79 COVID-19 patients were used. Indirect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific IgA, IgG, and IgG subtype specific enzyme-linked immunosorbent assays (ELISAs) were performed. Antibody titers between severe and nonsevere patients were compared at different times postonset of clinical symptoms. Titers in ELISA were compared to neutralizing antibody (Nab) titers determined by plaque reduction neutralization test (PRNT). Over 75% patients were positive for IgA/IgG antibodies in the first week. The ELISA titers did not differ during the first week; however, severe disease exhibited raised titers thereafter. Nab titers correlated with the ELISA titers in mild presentation but not in severe disease. IgA and IgG1 antibodies correlated stronger with Nabs. The findings highlighted that IgA together with IgG play an important in SARS-CoV-2 neutralization. These results will prove useful in assessing efficacy of vaccines and understanding disease pathogenesis.Harshad P Patil, Prajakta S Rane, Shubham Shrivastava, Sonali Palkar, Sanjay Lalwani, Akhilesh C Mishra, Vidya A Arankalle
1033 related Products with: Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients.
200ug200ul50 ug 200ul0,25ml / 50 test
Related Pathways
#33655833 2021/02/23
To Up
Comparison of the efficacy of HIV-1 Nef-Tat-Gp160-p24 polyepitope vaccine candidate with Nef protein in different immunization strategies.
One of the promising strategies for effective HIV-1 vaccine design involves finding the polyepitope immunogens using T cell epitopes.Fatemeh Namazi, Saba Davoodi, Azam Bolhassani
2497 related Products with: Comparison of the efficacy of HIV-1 Nef-Tat-Gp160-p24 polyepitope vaccine candidate with Nef protein in different immunization strategies.
100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100μg100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized
Related Pathways
#33655074 2021/02/04
To Up
IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells.
Therapeutic immunotoxins composed of antibodies and bacterial toxins provide potent activity against malignant cells, but joining them with a defined covalent bond while maintaining the desired function is challenging. Here, we develop novel immunotoxins by dovetailing full-length immunoglobulin G (IgG) antibodies and nontoxic anthrax proteins, in which the C terminus of the IgG heavy chain is connected to the side chain of anthrax toxin protective antigen. This strategy enabled efficient conjugation of protective antigen variants to trastuzumab (Tmab) and cetuximab (Cmab) antibodies. The conjugates effectively perform intracellular delivery of edema factor and N terminus of lethal factor (LF) fused with diphtheria toxin and Ras/Rap1-specific endopeptidase. Each conjugate shows high specificity for cells expressing human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), respectively, and potent activity across six Tmab- and Cmab-resistant cell lines. The conjugates also exhibit increased pharmacokinetics and pronounced in vivo safety, which shows promise for further therapeutic development.Zeyu Lu, Nicholas L Truex, Mariane B Melo, Yiran Cheng, Na Li, Darrell J Irvine, Bradley L Pentelute
2410 related Products with: IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells.
96T101000200 100 ug/vial500 1mg1001mg1 mg1mg
Related Pathways
#33653694 2021/03/02
To Up
SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study.
To evaluate the performance of new lateral flow immunoassays (LFIAs) suitable for use in a national coronavirus disease 2019 (covid-19) seroprevalence programme (real time assessment of community transmission 2-React 2).Maya Moshe, Anna Daunt, Barnaby Flower, Bryony Simmons, Jonathan C Brown, Rebecca Frise, Rebecca Penn, Ruthiran Kugathasan, Claire Petersen, Helen Stockmann, Deborah Ashby, Steven Riley, Christina Atchison, Graham P Taylor, Sutha Satkunarajah, Lenny Naar, Robert Klaber, Anjna Badhan, Carolina Rosadas, Federica Marchesin, Natalia Fernandez, Macià Sureda-Vives, Hannah Cheeseman, Jessica O'Hara, Robin Shattock, Gianluca Fontana, Scott J C Pallett, Michael Rayment, Rachael Jones, Luke S P Moore, Hutan Ashrafian, Peter Cherapanov, Richard Tedder, Myra McClure, Helen Ward, Ara Darzi, Paul Elliott, Graham S Cooke, Wendy S Barclay,
2440 related Products with: SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study.
100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized
Related Pathways
#33653382 2021/03/02
To Up
B cell-activating factors in autoimmune pulmonary alveolar proteinosis.
Autoimmune pulmonary alveolar proteinosis (APAP) results from the suppression of granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling by a neutralizing autoantibody against GM-CSF. B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are involved in immunoglobulin G production and are overproduced in various autoimmune disorders. We hypothesized that BAFF and/or APRIL levels would be elevated in serum and bronchoalveolar lavage fluid (BALF) and serum and BALF levels of BAFF and APRIL respond to the treatments (whole lung lavage (WLL) or inhalation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)) in patients with APAP.Masaki Hirose, Toru Arai, Chikatoshi Sugimoto, Takayuki Takimoto, Reiko Sugawara, Shojiro Minomo, Sayoko Shintani, Naoko Takeuchi, Kanako Katayama, Yasushi Inoue, Tomoko Kagawa, Takahiko Kasai, Masanori Akira, Yoshikazu Inoue
1850 related Products with: B cell-activating factors in autoimmune pulmonary alveolar proteinosis.
100 ug100ul100ug100ulcase100ug100ug Lyophilizedcase100 ml.500 ml1 L.
Related Pathways
#33652629 2021/02/26
To Up
Gastric Enzyme Supplementation Inhibits Food Allergy in a BALB/c Mouse Model.
Impaired gastric digestion due to suppressed gastric acidity enhances the risk for food allergy development. In the current study, we aimed to evaluate the impact of a supported gastric digestion via application of a pharmaceutical gastric enzyme solution (GES) on food allergy development and allergic reactions in a BALB/c mouse model. The ability of the GES to restore hypoacidic conditions was tested in mice treated with gastric acid suppression medication. To evaluate the impact on allergic symptoms, mice were orally sensitized with ovalbumin (OVA) under gastric acid suppression and subjected to oral challenges with or without GES. The immune response was evaluated by measurement of antibody titers, cytokine levels, mucosal allergy effector cell influx and regulatory T-cell counts. Clinical response was objectified by core body temperature measurements after oral OVA challenge. Supplementation of GES transiently restored physiological pH levels in the stomach after pharmaceutical gastric acid suppression. During oral sensitization, supplementation of gastric enzymes significantly reduced systemic IgE, IgG1 and IgG2a levels and allergic symptoms. In food allergic mice, clinical symptoms were reduced by co-administration of the gastric enzyme solution. Support of gastric digestion efficiently prevents food allergy induction and alleviates clinical symptoms in our food allergy model.Nazanin Samadi, Denise Heiden, Martina Klems, Martina Salzmann, Johanna Rohrhofer, Eleonore Weidmann, Larissa Koidl, Erika Jensen-Jarolim, Eva Untersmayr
2613 related Products with: Gastric Enzyme Supplementation Inhibits Food Allergy in a BALB/c Mouse Model.
100ul100.00 ug100ug100ug Lyophilized100ug Lyophilized100 μg4 Arrays/Slide4 Membranes/Box100 μg100ug100ug100 μg
Related Pathways
#33651919 2021/03/02
To Up
A solvent-free, catalyst-free formal [3+3] cycloaddition dearomatization strategy: towards new fluorophores for biomolecules labelling.
A general, sustainable dearomatization reaction for nitrogen-containing heterocycles was developed. Under solvent free conditions and without catalyst, the biorenewable methyl coumalate ( MC ) reacts as an efficient C3 partner to convert eleven types of basic aromatic rings into their pyrido[1,2-a] fused derivatives in good to excellent yields. The fluorescence properties of some of the products were harnessed to conjugate fluorescent tags to BSA and immunoglobulin G.Liang Chang, Nathalie Fischer-Durand, Geoffrey Gontard, Benoît Bertrand, Serge Thorimbert, Luc Dechoux
2691 related Products with: A solvent-free, catalyst-free formal [3+3] cycloaddition dearomatization strategy: towards new fluorophores for biomolecules labelling.
5L1 mg500g1 mg1 mg5 g 5 G100251 mg1 mg100 mg
Related Pathways
#33651853 2021/03/02
To Up
House dust mite sensitization drives cross-reactive immune responses to homologous helminth proteins.
The establishment of type 2 responses driven by allergic sensitization prior to exposure to helminth parasites has demonstrated how tissue-specific responses can protect against migrating larval stages, but, as a consequence, allow for immune-mediated, parasite/allergy-associated morbidity. In this way, whether helminth cross-reacting allergen-specific antibodies are produced and play a role during the helminth infection, or exacerbate the allergic outcome awaits elucidation. Thus, the main objective of the study was to investigate whether house dust mite (HDM) sensitization triggers allergen-specific antibodies that interact with Ascaris antigens and mediate antibody-dependent deleterious effects on these parasites as well as, to assess the capacity of cross-reactive helminth proteins to trigger allergic inflammation in house dust mite presensitized mice. Here, we show that the sensitization with HDM-extract drives marked IgE and IgG1 antibody responses that cross-react with Ascaris larval antigens. Proteomic analysis of Ascaris larval antigens recognized by these HDM-specific antibodies identified Ascaris tropomyosin and enolase as the 2 major HDM homologues based on high sequence and structural similarity. Moreover, the helminth tropomyosin could drive Type-2 associated pulmonary inflammation similar to HDM following HDM tropomyosin sensitization. The HDM-triggered IgE cross-reactive antibodies were found to be functional as they mediated immediate hypersensitivity responses in skin testing. Finally, we demonstrated that HDM sensitization in either B cells or FcγRIII alpha-chain deficient mice indicated that the allergen driven cell-mediated larval killing is not antibody-dependent. Taken together, our data suggest that aeroallergen sensitization drives helminth reactive antibodies through molecular and structural similarity between HDM and Ascaris antigens suggesting that cross-reactive immune responses help drive allergic inflammation.Pedro Henrique Gazzinelli-Guimaraes, Sasisekhar Bennuru, Rafael de Queiroz Prado, Alessandra Ricciardi, Joshua Sciurba, Jonah Kupritz, Matthew Moser, Olena Kamenyeva, Thomas B Nutman
1086 related Products with: House dust mite sensitization drives cross-reactive immune responses to homologous helminth proteins.
1mg100ug100ug 1 mg 1mg1mg501 mg101mg5
Related Pathways
#33650699 2021/03/02
To Up
Targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases and maternal-fetal immune cytopenias.
FcRn, a non-classical Fc gamma (γ) receptor (FcγR) with near ubiquitous expression, plays key roles in disease pathogenesis and progression though immunoglobulin G (IgG) transport, IgG recycling, and IgG-immune complex clearance. FcRn function can be inhibited using IgG-based and non-IgG-based antagonists, by exploiting the pH-dependent binding affinity of FcRn for the IgG Fc region. FcRn therapeutics have shown promise in murine models and human clinical trials for autoimmune diseases and maternal-fetal immune cytopenias; they appear safe, well-tolerated, and reduce circulating IgG levels. Compared to traditional therapeutics, inhibiting FcRn has fewer adverse side effects and represents a new approach that is less invasive, time-consuming, and costly.Sarah L Wyckoff, Krystalyn E Hudson